Released : July 05, 2019 16:42 RNS Number : 7002E MaxCyte, Inc. 05 July 2019 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
Released : July 05, 2019 16:36 RNS Number : 6992E MaxCyte, Inc. 05 July 2019 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the
Released : June 19, 2019 07:00 RNS Number : 7254C MaxCyte, Inc. 19 June 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") 2018 Annual Report Gaithersburg, Maryland - 19 June 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that
Released : June 12, 2019 07:00 RNS Number : 8822B MaxCyte, Inc. 12 June 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Appointment of Joint Corporate Broker Gaithersburg, Maryland - 12 JUNE 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage, cell-based therapies and life
Released : May 29, 2019 07:00 RNS Number : 3926A MaxCyte, Inc. 29 May 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Save the Date: Capital Markets Day Gaithersburg, Maryland - 29 MAY 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Released : May 08, 2019 16:41 RNS Number : 4229Y MaxCyte, Inc. 08 May 2019 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
Released : May 08, 2019 16:36 RNS Number : 4224Y MaxCyte, Inc. 08 May 2019 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the
Released : May 08, 2019 07:00 RNS Number : 2936Y MaxCyte, Inc. 08 May 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform - No dose-limiting toxicities or safety concerns observed in
Released : May 01, 2019 07:00 RNS Number : 6577X MaxCyte, Inc. 01 May 2019 MaxCyte Presents at 22 nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing - CARMA drug candidates can be manufactured via streamlined,
Released : April 24, 2019 07:00 RNS Number : 8683W MaxCyte, Inc. 24 April 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2018 ¾ First CARMA™ cell therapeutic programme targeting treatment of solid tumours has advanced into
